Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Women's Health and Genetics/Laboratory Corporation of America, |
RCV001328460 | SCV001519602 | likely benign | not specified | 2021-03-10 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001456317 | SCV001660095 | likely benign | RASopathy | 2024-01-26 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002322261 | SCV002609994 | likely benign | Cardiovascular phenotype | 2022-06-09 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Fulgent Genetics, |
RCV002493717 | SCV002801291 | likely benign | Noonan syndrome 1; Juvenile myelomonocytic leukemia; Metachondromatosis; LEOPARD syndrome 1 | 2021-08-27 | criteria provided, single submitter | clinical testing | |
Ce |
RCV003456490 | SCV004184272 | likely benign | not provided | 2023-10-01 | criteria provided, single submitter | clinical testing | PTPN11: BP4, BP7 |